We evaluated @ patients with nonalcoholic fatty liver disease ( NAFLD ) , @ patients with biopsy-proven hepatitis C ( @ patients with fatty liver and @ patients without fatty liver ) , @ patients with inflammatory bowel disease ( IBD ) , and @ patients with dyspepsia .